RTP Mobile Logo
Current Clinical Controversies and Promising Therapeutic Strategies in Advanced Prostate Cancer: A Live Clinical Investigator Think Tank
Released May 2013

Proceedings from a CME symposium held at the 2013 Genitourinary Cancers Symposium. Featuring perspectives from Drs Daniel J George, Robert Dreicer, A Oliver Sartor, Celestia S Higano and Christopher J Logothetis. (Video Program)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE

    This activity has been designed to meet the educational needs of medical and radiation oncologists, urologists and other allied healthcare professionals.

    OVERVIEW OF ACTIVITY

    Cancer of the genitourinary system affects hundreds of thousands of individuals within the United States each year and accounts for almost 30% of all newly diagnosed tumors in humans. Tumors of the prostate are among the most prevalent and thus a topic of extensive ongoing clinical research. Consequently, the management of prostate cancer is continuously in a state of evolution, necessitating rapid and consistent access to learning opportunities for medical oncologists, radiation oncologists, urologists and other healthcare providers who treat the disease. These proceedings from an interactive CME symposium held during the 2013 Genitourinary Cancers Symposium offer medical professionals a multifaceted educational experience focused specifically on the current treatment of prostate cancer.

    LEARNING OBJECTIVES

    • Review the known efficacy and safety data related to radium-223 chloride in patients with skeletal metastases in preparation for its potential approval.
    • Recall existing and emerging research information demonstrating the impact of secondary hormonal interventions on quality and quantity of life for patients with chemotherapy-naïve or pretreated castration-resistant prostate cancer, and use this information to guide treatment planning for these patients.
    • Recognize the unique patterns of response with available and emerging immunotherapeutic strategies, and effectively counsel patients considering these treatments.
    • Effectively apply evidence-based research findings in the determination of best-practice sequencing of available immunotherapeutics, chemotherapeutics and secondary hormonal agents for patients with metastatic prostate cancer.
    • Explore the emerging data and active research evaluating novel agents in the setting of advanced prostate cancer in order to prioritize clinical trial opportunities for appropriate patients.

    ACCREDITATION STATEMENT

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.


    CME credit is no longer available for this issue

    CREDIT DESIGNATION STATEMENT


    CME credit is no longer available for this issue

    HOW TO USE THIS CME ACTIVITY

    This CME activity consists of a video component. The participant should watch the video.


    CME credit is no longer available for this issue

    CONTENT VALIDATION AND DISCLOSURES

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Daniel J George, MD
    Associate Professor of Medicine and Surgery
    Director of Genitourinary Oncology Program
    Duke Cancer Institute
    Durham, North Carolina

    Advisory Committee: Aveo Pharmaceuticals, Dendreon Corporation, Medivation Inc, Pfizer Inc, Sanofi, Viamet Pharmaceuticals Inc; Consulting Agreements: Astellas, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Dendreon Corporation, Exelixis Inc, Genentech BioOncology, Medivation Inc, Molecular Insight, Novartis Pharmaceuticals Corporation, Pfizer Inc, Roche Laboratories Inc, Sanofi, Teva Oncology; Contracted Research: Exelixis Inc, Genentech BioOncology, GlaxoSmithKline, Janssen Pharmaceuticals Inc, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Pfizer Inc, Roche Laboratories Inc; Speakers Bureau: Dendreon Corporation, Novartis Pharmaceuticals Corporation, Pfizer Inc, Sanofi.

    Robert Dreicer, MD, MS
    Chairman, Department of Solid Tumor Oncology
    Taussig Cancer Institute
    Cleveland Clinic
    Professor of Medicine
    Cleveland Clinic Lerner College of Medicine
    Cleveland, Ohio

    Advisory Committee: EMD Serono Inc, Janssen Pharmaceuticals Inc, Lilly USA LLC, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation.

    A Oliver Sartor, MD
    Medical Director, Tulane Cancer Center
    Laborde Professor of Cancer Research
    Professor of Medicine and Urology
    Tulane Medical School
    New Orleans, Louisiana

    Advisory Committee: Bayer HealthCare Pharmaceuticals, Sanofi; Consulting Agreements: Algeta ASA, Bayer HealthCare Pharmaceuticals, Celgene Corporation, GlaxoSmithKline, Medivation Inc, Millennium: The Takeda Oncology Company, OncoGenex Pharmaceuticals Inc, Pfizer Inc, Sanofi; Contracted Research: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Millennium: The Takeda Oncology Company, Sanofi.

    Celestia S Higano, MD
    Professor of Medicine and Urology
    University of Washington School of Medicine
    Member, Fred Hutchinson Cancer Research Center
    Seattle Cancer Care Alliance
    Seattle, Washington

    Advisory Committee: Amgen Inc, Aragon Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Dendreon Corporation, Endo Pharmaceuticals, Exelixis Inc, Medivation Inc, Millennium: The Takeda Oncology Company, National Cancer Institute, Novartis Pharmaceuticals Corporation, OncoGenex Pharmaceuticals Inc, Teva Oncology, US Department of Defense, Veridex LLC; Consulting Agreements: Amgen Inc, Aragon Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Dendreon Corporation, Exelixis Inc, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Medivation Inc, Millennium: The Takeda Oncology Company, National Cancer Institute, Novartis Pharmaceuticals Corporation, OncoGenex Pharmaceuticals Inc, Teva Oncology, US Department of Defense; Contracted Research: Aragon Pharmaceuticals, Dendreon Corporation, Exelixis Inc, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Medivation Inc, Millennium: The Takeda Oncology Company, National Cancer Institute, OncoGenex Pharmaceuticals Inc, Teva Oncology, US Department of Defense.

    Christopher J Logothetis, MD
    Chairman/Professor, Genitourinary Medical Oncology
    The University of Texas MD Anderson Cancer Center
    Houston, Texas

    Paid Research: Dendreon Corporation, Johnson & Johnson Pharmaceuticals.

    MODERATORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Algeta US, Allos Therapeutics, Amgen Inc, ArQule Inc, Astellas, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Foundation Medicine Inc, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Lilly USA LLC, Medivation Inc, Merck, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc and Teva Oncology.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Algeta US/Bayer HealthCare Pharmaceuticals, Astellas/Medivation Inc, Dendreon Corporation, Millennium: The Takeda Oncology Company and Teva Oncology.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
    Adobe Flash Player 10.2 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: May 2013
    Expiration date: May 2014

Acknowledge and close

Watch video
(WIFI is recommended for best performance):

Introduction Dr Love
Module 1: Dr George Next-Generation Lyase Inhibitors
Module 2: Dr Dreicer Novel Antiandrogens
Module 3: Dr Sartor Radium-223
Module 4: Dr Higano Immune Therapy
Module 5: Dr Logothetis New Agents in Development